<?xml version="1.0" encoding="UTF-8"?>
<p id="Par69">Clinical trials to study the effect of the presence of additional M2e antigens in the trivalent vaccine have shown that, in the case of a weak response to the main vaccine, the M2e component can significantly enhance the immune response [
 <xref ref-type="bibr" rid="CR117">117</xref>]. Thus, additional M2e epitopes will be able to have a “safety net” function when such vaccines are introduced into wide practice.
</p>
